Cyclic peptide inhibitors of hedgehog proteins
OwnerRudi Fasan, Andrew Owensinventors
Life of this patent
Estimating the term…
Abstract
Cyclic peptide compounds are provided that can bind to one or more homologs of Hedghehog signaling proteins and block their interaction with the Patched receptor. These compounds are useful for suppressing Hedgehog-dependent stimulation of the Hedgehog pathway in cells and in living organisms. Methods for using the cyclic peptide compounds, and compositions comprising them, for treatment of cancers and other diseases which are characterized by aberrant Hedgehog-dependent activation of the Hedgehog pathway and/or which can benefit from chemical suppression of Hedgehog-dependent signaling are also disclosed.
Claims21
A cyclic peptide of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof:
- wherein:
- X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, Tyr, substituted Phe, substituted Tyr, or substituted Trp;
- X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, Thr, Nval, Nleu, substituted Phe, substituted Tyr, or substituted Trp;
- X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, Arg, Orn, Dab, Dap, Nleu, or Nval;
- X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, Glu, Aib, substituted Phe, substituted Tyr, substituted Trp, or an amino acid of formula (IV)
- wherein:
- q is 0, 1, or 2;
- and Ar is a C5-C15 aryl group or a C5-C15 substituted aryl group;
- X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, Lys, Orn, Dab, Dap, substituted Phe, substituted Tyr, substituted Trp, Nval, or Nleu;
- X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, Asp, Orn, Dab, Dap, substituted Phe, substituted Tyr, substituted Trp, Aib, 3,3,3-trifluoro-alanine, alpha,alpha-bis-trifluoromethyl-glycine, or 2-cyclopropylglycine;
- X8 is Met, Nleu, Gly, or Pro;
- X9 is Asp, Glu, Cys, His, or an amino acid residue of formula (III)
- wherein:
- q is 0, 1, or 2;
- and Z3 is selected from the group consisting of —CONHOH, —N(OH)COCH3, —CONHOCH3, —ONHCOCH3, —P(=O)(OH)2, —P(═O)H(OH), —SO3H, —SO2NH2, —NHSO2CH3, —CONHSO2CH3, —NHCONHSO2CH3, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, —CH(OH)CF3, —C(OH)2CF3, thiazolidine-2,4-dione, oxazolidine-2,4-dione, 1,2,4-oxadiazol-5(4H)-one, 1,2,4-thiadiazol-5(4H)-one, 3H-1,2,3,5-oxathiadiazole 2-oxide, 1,2,4-oxadiazole-5(4H)-thione, isoxazol-3-ol, isothiazol-3-ol, pyrrolidine-2,4-dione, furan-2,4(3H,5H)-dione, 3-hydroxycyclopent-2-enone, 3-hydroxycyclobut-3-ene-1,2-dione, and 2,6-difluorophenol;
- X10 is Gly, Met, D-Met, Nleu, D-Nleu, Thr, D-Thr, Ser, D-Ser, or —N(R9)CH2C(O)—, wherein R9 is a C1-C15 aliphatic, C1-C15 substituted aliphatic, C5-C15 aryl, C5-C15 substituted aryl, C6-C15 alkylaryl, or C6-C15 substituted alkylaryl group;
- X12 is Ser, Thr, Met, Leu, Ile, Val, Nleu, or Nval;
- X13 is Asp, Glu, or absent;
- X5 is Met, Gly, or Nleu;
- R1 is hydrogen, an acetyl group, a label molecule, or a R13CO— group, wherein R13 is C5-C15 alkanoic acid or C5-C15 alkenoic acid;
- R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
- R4 is hydrogen, or a linear or branched alkyl group comprising between one and eight carbon atoms;
- R12 is —OH or NH2;
- L1 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 6 and 15 Angstrom units;
- and
- L2 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 5 and 12 Angstrom units;
- and wherein the cyclic peptide is able to bind at least one homolog of a Hedgehog protein.
A cyclic peptide of Formula (I), or a pharmaceutically acceptable salt thereof:
- wherein:
- X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, or Tyr;
- X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, or Thr;
- X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, Gly, Pro, Ala, Trp or Arg;
- X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, or Glu;
- X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, or Lys;
- X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, or Asp;
- X8 is Met, Nleu, Gly, or Pro;
- X9 is Asp or Glu;
- X10 is Gly, Met, Nleu, Thr, or Ser;
- X12 is Ser, Thr, Met, Leu, Ile, or Val;
- X13 is Asp, Glu, or absent;
- R1 is hydrogen, an acetyl group, or an acyl group;
- R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
- R4 is hydrogen, or a linear or branched alkyl group comprising between one and eight carbon atoms;
- R12 is —OH or NH2;
- and
- L1 is a linker unit, such that the linear dimension between the Ca carbon atoms connected by the linker unit is between about 6 and 15 Angstrom units.
A cyclic peptide of Formula (II), or a pharmaceutically acceptable salt thereof:
- wherein:
- X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, or Tyr;
- X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, or Thr;
- X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, or Arg;
- X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, or Glu;
- X5 is Met or Gly;
- X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, or Lys;
- X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, or Asp;
- X9 is Asp or Glu;
- X10 is Gly, Met, Nleu, Thr, or Ser;
- X12 is Ser, Thr, Met, Leu, Ile, or Val;
- X13 is Asp, Glu, or absent;
- R1 is hydrogen, an acetyl group, or an acyl group;
- R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
- R4 is hydrogen or an alkyl group comprising between one and eight carbon atoms;
- R12 is —OH or NH2;
- and
- L2 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 5 and 12 Angstrom units.
21-25. (canceled)
Dependencies are inferred from the claim text.